4D pharma to Present Additional Data from Phase II Study of Blautix for the Treatment of Irritable Bowel Syndrome at Digestiv...
May 17 2021 - 6:00AM
Business Wire
Company will host conference call on Tuesday,
May 25, 2021 at 12:00 p.m. EDT
4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical
company leading the development of Live Biotherapeutic products
(LBPs) - a novel class of drug derived from the microbiome, today
announced that it will present data from its Phase II study of
single strain LBP Blautix® in patients with irritable bowel
syndrome (IBS) subtypes IBS-C and IBS-D in a poster session at
Digestive Disease Week (DDW) 2021, taking place virtually May
21-23, 2021.
Details of the poster presentation are as follows:
Presentation Title: A Phase II Study of Live
Biotherapeutic Blautix in Irritable Bowel Syndrome (IBS) Patients
with Subtypes IBS-C and IBS-D. Session Date & Time:
Saturday, May 22, 2021 from 12:15pm to 1:00pm EDT (5:15pm to 6:00pm
BST) Session Title: Microbial-Based Therapy
Presenter: Eamonn Quigley, M.D. Chief, Division of
Gastroenterology and Hepatology at Houston Methodist Abstract
Number: 3525656
4D pharma will host a virtual event to review the additional
data presented at DDW 2021 and how this relates to the current IBS
treatment landscape. The event will take place on Tuesday, May 25,
2021 at 5:00pm BST (12:00pm EDT). The event will feature a
presentation from 4D pharma management followed by an analyst
Q&A session.
A live webcast of the event will be available via the Events
section of the 4D pharma website at www.4dpharmaplc.com. To access
the call, please dial +1-760-294-1674 (United States) or
+44-203-059-58-69 (United Kingdom) and reference Conference ID
20210360. A replay of the webcast will be available following the
event.
About 4D pharma
4D pharma is a world leader in the development of Live
Biotherapeutics, a novel and emerging class of drugs, defined by
the FDA as biological products that contain a live organism, such
as a bacterium, that is applicable to the prevention, treatment or
cure of a disease. 4D has developed a proprietary platform,
MicroRx®, that rationally identifies Live Biotherapeutics based on
a deep understanding of function and mechanism.
4D pharma's Live Biotherapeutic products (LBPs) are orally
delivered single strains of bacteria that are naturally found in
the healthy human gut. The Company has six clinical programs,
namely a Phase I/II study of MRx0518 in combination with KEYTRUDA
(pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a
neoadjuvant setting for patients with solid tumors, a Phase I study
of MRx0518 in patients with pancreatic cancer, a Phase I/II study
of MRx-4DP0004 in asthma, a Phase II study of MRx-4DP0004 in
patients hospitalized with COVID-19, and Blautix® in Irritable
Bowel Syndrome (IBS) which has completed a successful Phase II
trial. Preclinical-stage programs include candidates for CNS
disease such as Parkinson's disease and other neurodegenerative
conditions. The Company has a research collaboration with MSD, a
tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to
discover and develop Live Biotherapeutics for vaccines.
For more information, refer to https://www.4dpharmaplc.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210517005223/en/
4D pharma Investor Relations: ir@4dpharmaplc.com
N+1 Singer - Nominated Adviser and Joint Broker +44 (0)20 7496
3000 Philip Davies / Iqra Amin / James Fischer (Corporate Finance)
Tom Salvesen (Corporate Broking)
Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332
2500 Dominic Wilson / Phil Walker
Stern Investor Relations, Inc. +1-212-362-1200 Julie Seidel
Julie.seidel@sternir.com
Image Box Communications +44 (0)20 8943 4685 Neil Hunter /
Michelle Boxall neil@ibcomms.agency / michelle@ibcomms.agency
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Mar 2024 to Apr 2024
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Apr 2023 to Apr 2024